Abstract
Background: The incidence of diabetes is increasing steeply; the number of diabetics has doubled over the past three decades. Surprisingly, the knowledge of type 3c diabetes mellitus (T3cDM) is still unclear to the researchers, scientist and medical practitioners, leading towards erroneous diagnosis, which is sometimes misdiagnosed as type 1 diabetes mellitus (T1DM), or more frequently type 2 diabetes mellitus (T2DM). This review is aimed to outline recent information on the etiology, pathophysiology, diagnostic procedures, and therapeutic management of T3cDM patients.
Methods: The literature related to T3cDM was thoroughly searched from the public domains and reviewed extensively to construct this article. Further, existing literature related to the other forms of diabetes is reviewed for projecting the differences among the different forms of diabetes. Detailed and updated information related to epidemiological evidence, risk factors, symptoms, diagnosis, pathogenesis and management is structured in this review.
Results: T3cDM is often misdiagnosed as T2DM due to the insufficient knowledge differentiating between T2DM and T3cDM. The pathogenesis of T3cDM is explained which is often linked to the history of chronic pancreatitis, pancreatic cancer. Inflammation, and fibrosis in pancreatic tissue lead to damage both endocrine and exocrine functions, thus leading to insulin/glucagon insufficiency and pancreatic enzyme deficiency.
Conclusion: Future advancements should be accompanied by the establishment of a quick diagnostic tool through the understanding of potential biomarkers of the disease and newer treatments for better control of the diseased condition.
Keywords: Type 3c diabetes mellitus, insulin, glucagon, pancreatogenic diabetes, chronic pancreatitis, pancreatic ductal adenocarcinoma.
[1]
International Diabetes Federation. IDF diabetes atlas.8th ed. Brussels
Belgium: International Diabetes Federation; 2017.Available
from: . diabetesatlas.org (http://www.diabetesatlas.org) [Cited: 1st
June 2018].
[2]
American Diabetes Association AD. Diagnosis and classification of
diabetes mellitus. Diabetes Care 2012; 35(Suppl. 1): S64-71.
[3]
Petrov MS. Diabetes of the exocrine pancreas: American Diabetes Association-compliant lexicon. Pancreatology 2017; 17(4): 523-6.
[4]
Woodmansey C, McGovern AP, McCullough KA, et al. Incidence, demographics, and clinical characteristics of diabetes of the exocrine pancreas (Type 3c): a retrospective cohort study. Diabetes Care 2017; 40(11): 1486-93.
[5]
Henzen C. Secondary forms of diabetes mellitus. In: Kahn CR WG,, Ed. Praxis. New York: Lea & Febiger 2009; pp. 1135-40.
[6]
Alberti KGMM. Diabetes secondary to pancreatopathy: an example
of brittle diabetes. In: Tiengo A,, Alberti KGMM,, Del Prato S VM,, Eds. Diabetes secondary to pancreatopathy proceedings of the post
easd international symposium on diabetes secondary to
pancreatopathy, Padova, 21-22 September 1987, International
Congress Series 762.. Amsterdam: Excerpta Medica . 1988; pp. 211-4.
[7]
Ewald N, Hardt PD. Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. World J Gastroenterol 2013; 19(42): 7276.
[8]
Ewald N, Kaufmann C, Raspe A, et al. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev 2012; 28(4): 338-42.
[9]
Hart PA, Bellin MD, Andersen DK, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol 2016; 1(3): 226-37.
[10]
Shen HN, Yang CC, Chang YH, Lu CL, Li CY. Risk of diabetes mellitus after first attack acute pancreatitis: a national population-based study. Am J Gastroenterol 2015; 110(12): 1698.
[11]
Lee YK, Huang MY, Hsu CY, Su YC. Bidirectional relationship between diabetes and acute pancreatitis: a population-based cohort study in Taiwan. Medicine 2016; 95(2)e2448
[12]
Pendharkar SA, Mathew J, Petrov MS. Age- and sex-specific
prevalence of diabetes associated with diseases of the exocrine
pancreas: a population based study. Dig Liver Dis 2017; 49:: 540e4..
[13]
Keller J, Layer P. Diagnosis of pancreatic exocrine insufficiency in
chronic pancreatitis. Pancreapedia: Exocrine pancreas knowledge
base 2015.Available from: . pancreapedia.org/reviews/diagnosis-of-pancreatic-exocrine-insufficiency-in-chronic-pancreatitishttps://www.pancreapedia.org/reviews/diagnosis-of-pancreatic-exocrine-insufficiency-in-chronic-pancreatitis [Cited 28th May 2018].
[14]
Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 2014; 13(6): 465-76.
[15]
Cersosimo E, Pisters PW, Pesola G, McDermott K, Bajorunas D, Brennan MF. Insulin secretion and action in patients with pancreatic cancer. Cancer 1991; 67(2): 486-93.
[16]
Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134(4): 981-7.
[17]
Permert J, Liu J, Larsson J, Adrian TE. Is impaired insulin-receptor binding involved in the impaired glucose metabolism and cachexia of pancreatic cancer patients? Clin Nutr 1993; 12: 31.
[18]
Permert J, Adrian TE, Jacobsson P, Jorfelt L, Fruin AB, Larsson J. Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor? Am J Surg 1993; 165(1): 61-7.
[19]
Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134(1): 95-101.
[20]
Aggarwal G, Rabe KG, Petersen GM, Chari ST. New-onset diabetes in pancreatic cancer: A study in the primary care setting. Pancreatology 2012; 12(2): 156-61.
[21]
Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology 2001; 121(3): 640-5.
[22]
Gullo L, Pezzilli R, Morselli-Labate AM. Group the IPCS.
Diabetes and the Risk of Pancreatic Cancer. N Engl J Med 1994; 331(2): 81-4.
[23]
Malka D, Hammel P, Sauvanet A, et al. Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology 2000; 119(5): 1324-32.
[24]
Mohapatra S, Majumder S, Smyrk TC, et al. Diabetes mellitus is associated with an exocrine pancreatopathy. Pancreas 2016; 45(8): 1104-10.
[25]
Andersen DK, Andren-Sandberg Å, Duell EJ, et al. Pancreatitisdiabetes-
pancreatic cancer: Summary of an NIDDK-NCI
workshop. Pancreas 2013; 42(8)
[http://dx.doi.org/10.1097/MPA.0b013e3182a 9ad9d.]
[http://dx.doi.org/10.1097/MPA.0b013e3182a 9ad9d.]
[26]
Domschke S, Stock KP, Pichl J, Schneider MU, Domschke W. Beta-cell reserve capacity in chronic pancreatitis. Hepatogastroenterology 1985; 32: 27-30.
[27]
Andersen DK, Korc M, Petersen GM, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes 2017; 66(5): 1103-10.
[28]
Ballian N, Brunicardi FC. Islet vasculature as a regulator of endocrine pancreas function. World J Surg 2007; 31(4): 705-14.
[29]
Korc MU, Iwamoto YA, Sankaran HA, Williams JA, Goldfine ID. Insulin action in pancreatic acini from streptozotocin-treated rats. I. Stimulation of protein synthesis. Am J Physiol 1981; 240(1): G56-62.
[30]
Sankaran HA, Iwamoto YA, Korc MU, Williams JA, Goldfine ID. Insulin action in pancreatic acini from streptozotocin-treated rats. II. Binding of 125I-insulin to receptors. Am J Physiol 1981; 240(1): G63-8.
[31]
Gudipaty L, Rickels MR. Pancreatogenic (Type 3c) diabetes. Pancreapedia: Exocrine pancreas knowledge base 2015.Available
from: . pancreapedia.org/reviews/pancreatogenic-type-3c-diabeteshttps://www.pancreapedia.org/reviews/pancreatogenic-type-3c-diabetes
[33]
Kloppel G, Bommer G, Commandeur G, Heitz P. The endocrine pancreas in chronic pancreatitis. Immunocytochemical and ultrastructural studies. Virchows Arch A 1978; 377(2): 157-74.
[34]
Sasikala M, Talukdar R, Radhika G, et al. β-Cell Dysfunction in Chronic Pancreatitis. Dig Dis Sci 2012; 57(7): 1764-72.
[35]
Seymour NE, Brunicardi FC, Chaiken RL, et al. Reversal of
abnormal glucose production after pancreatic resection by
pancreatic polypeptide administration in man. Surgery 1988; 104(2): 119-29.
[36]
Makuc J. Management of pancreatogenic diabetes: challenges and solutions. Diabetes Metab Syndr Obes 2016; 9: 311-5.
[37]
Andersen BN, Krarup T, Pedersen NT, Faber OK, Hagen C, Worning H. B cell function in patients with chronic pancreatitis and its relation to exocrine pancreatic function. Diabetologia 1982; 23: 86-9.
[38]
Knop FK, Vilsboll T, Larsen S, Madsbad S, Holst JJ, Krarup T. Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis. Regul Pept 2010; 164: 144-50.
[39]
Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. Pancreatology 2011; 11: 279-94.
[40]
Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965; 14(10): 619-33.
[42]
Chari ST, Zapiach M, Yadav D, Rizza RA. β-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance. Pancreatology 2005; 5: 229-33.
[43]
Aggarwal G, Ramachandran V, Javeed N, et al. Adrenomedullin is upregulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. Gastroenterology 2012; 143: 1510-7.
[44]
Sekine N, Takano K, Kimata-Hayashi N, Kadowaki T, Fujita T. Adrenomedullin inhibits insulin exocytosis via pertussis toxin-sensitive G protein-coupled mechanism. Am J Physiol Endocrinol Metab 2006; 291: E9-E14.
[45]
Ramachandran V, Arumugam T, Langley R, et al. The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. PLoS One 2009; 4e7502
[46]
Ramachandran V, Arumugam T, Hwang RF, Greenson JK, Simeone DM, Logsdon CD. Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR. Cancer Res 2007; 67: 2666-75.
[47]
Keleg S, Kayed H, Jiang X, et al. Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. Int J Cancer 2007; 121: 21-32.
[48]
Vlasakova Z, Bartos V, Spicak J. Diabetes mellitus in chronic pancreatitis and insulin sensitivity. Vnitr Lek 2002; 48: 878-81.
[49]
Yki-Jarvinen H, Kiviluoto T, Taskinen MR. Insulin resistance is a prominent feature of patients with pancreatogenic diabetes. Metabolism 1986; 35: 718-27.
[50]
Nosadini R, Del Prato S, Tiengo A, et al. Insulin sensitivity, binding, and kinetics in pancreatogenic and type I diabetes. Diabetes 1982; 31: 346-55.
[51]
Muggeo M, Moghetti P, Faronato PP, et al. Insulin receptors on circulating blood cells from patients with pancreatogenic diabetes: a comparison with type I diabetes and normal subjects. J Endocrinol Invest 1987; 10: 311-9.
[52]
Malecka-Panas E, Gasiorowska A, Kropiwnicka A, Zlobinska A, Drzewoski J. Endocrine pancreatic function in patients after acute pancreatitis. Hepatogastroenterology 2002; 49: 1707-12.
[53]
Perusicov’a J. Glucose tolerance and secretion of insulin in chronic pancreatitis. Acta Univ Carol Med Monogr 1989; 131: 1-92.
[54]
Pendharkar SA, Asrani VM, Xiao AY, et al. Relationship between pancreatic hormones and glucose metabolism: a cross-sectional study in patients after acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 2016; 311: G50-8.
[55]
Brunicardi FC, Chaiken RL, Ryan AS, et al. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab 1996; 81(10): 3566-72.
[56]
Seymour NE, Turk JB, Laster MK, et al. In vitro hepatic insulin resistance in chronic pancreatitis in the rat. J Surg Res 1989; 46(5): 450-6.
[57]
Seymour NE, Volpert AR, Lee EL, Andersen DK, Hernandez C. Alterations in hepatocyte insulin binding in chronic pancreatitis: Effects of pancreatic polypeptide. Am J Surg 1995; 169(1): 105-10.
[58]
Goldstein JA, Kirwin JD, Seymour NE, Trachtenberg JE, Rademaker EA, Andersen DK. Reversal of in vitro hepatic insulin
resistance in chronic pancreatitis by pancreatic polypeptide in the
rat. Surgery 1989; 106(6): 1128-32-3..
[59]
Rabiee A, Galiatsatos P, Salas-Carrillo R, Thompson MJ, Andersen DK, Elahi D. Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy. J Diabetes Sci Technol 2011; 5(6): 1521-8.
[60]
Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 2005; 11(2): 183-90.
[61]
Andersson AK, Flodström M, Sandler S. Cytokine-induced inhibition of insulin release from mouse pancreatic β-cells deficient in inducible nitric oxide synthase. Biochem Biophys Res Commun 2001; 281(2): 396-403.
[62]
Pondugala PK, Sasikala M, Guduru VR, Rebala P, Reddy DN. Interferon-γ decreases nuclear localization of Pdx-1 and triggers β-cell dysfunction in chronic pancreatitis. J Interferon Cytokine Res 2015; 35(7): 523-9.
[63]
Fujimoto K, Polonsky KS. Pdx1 and other factors that regulate pancreatic beta-cell survival. Diabetes Obes Metab 2009; 11(Suppl. 4): 30-7.
[64]
Huang H, Dong X, Kang MX, et al. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. Am J Gastroenterol 2010; 105(7): 1661-9.
[65]
Sah RP, Nagpal SJS, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 2013; 10(7): 423-33.
[66]
Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993; 80(8): 1047-50.
[67]
Permert J, Larsson J, Fruin AB, Tatemoto K, Herrington MK, Adrian TE. Islet hormone secretion in pancreatic cancer patients with diabetes. Pancreas 1997; 15(1): 60-8.
[68]
Permert J, Larsson J, Westermark GT, et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 1994; 330(5): 313-8.
[69]
Gebhardt C, Németh J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006; 72(11): 1622-31.
[70]
Pfeffer F, Koczan D, Adam U, et al. Expression of connexin26 in islets of Langerhans is associated with impaired glucose tolerance in patients with pancreatic adenocarcinoma. Pancreas 2004; 29(4): 284-90.
[71]
Liou GY, Döppler H, Necela B, et al. Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs. J Cell Biol 2013; 202(3): 563-77.
[72]
Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007; 67(19): 9518-27.
[73]
Basso D, Greco E, Fogar P, et al. Pancreatic cancer-derived S-100A8 N-terminal peptide: A diabetes cause? Clin Chim Acta 2006; 372(1-2): 120-8.
[74]
Wang WS, Liu XH, Liu LX, Jin DY, Yang PY, Wang XL. Identification of proteins implicated in the development of pancreatic cancer-associated diabetes mellitus by iTRAQ-based quantitative proteomics. J Proteomics 2013; 84: 52-60.
[75]
Moz S, Basso D, Padoan A, et al. Blood expression of matrix metalloproteinases 8 and 9 and of their inducers S100A8 and S100A9 supports diagnosis and prognosis of PDAC-associated diabetes mellitus. Clin Chim Acta 2016; 456: 24-30.
[76]
Sarén P, Welgus HG, Kovanen PT. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 1996; 157(9): 4159-65.
[77]
Xu K, Geczy CL. IFN-gamma and TNF regulate macrophage expression of the chemotactic S100 protein S100A8. J Immunol 2000; 164(9): 4916-23.
[78]
Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006; 4(1): 48.
[80]
Flatt PR, Green BD. Nutrient regulation of pancreatic beta-cell function in diabetes: problems and potential solutions. Biochem Soc Trans 2006; 34: 774-8.
[81]
Stonehouse AH, Holcombe JH, Kendall DM. Management of type 2 diabetes: the role of incretin mimetics. Expert Opin Pharmacother 2006; 7: 2095-105.
[82]
Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49: 741-8.
[83]
Ebert R, Creutzfeldt W. Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia 1980; 19: 198-204.
[84]
Kuo P, Stevens JE, Russo A, et al. Gastric emptying, incretin hormone secretion and postprandial glycemia in cystic fibrosis— effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab 2011; 96: 851-5.
[85]
Knop FK, Vilsbøll T, Larsen S, et al. Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab 2007; 292: E324-30.
[86]
Hornum M, Pedersen JF, Larsen S, Olsen O, Holst JJ, Knop FK. Increased postprandial response of glucagon-like peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency. Pancreatology 2010; 10: 201-17.
[87]
Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008; 359: 2208-19.
[88]
Liu QC, Zhuang ZH, Zeng K, Cheng ZJ, Gao F, Wang ZQ. Prevalence of pancreatic diabetes in patients carrying mutations or polymorphisms of the PRSS1 gene in the Han population. Diabetes Technol Ther 2009; 11(12): 799-804.
[89]
Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324(5924): 217.
[90]
Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012; 2: 41-6.
[91]
Hu C, Hart SN, Bamlet WR, et al. Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients. Cancer Epidemiol Biomarkers Prev 2016; 25: 207-11.
[92]
Wang L, Brune KA, Visvanathan K, et al. Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 2829-34.
[94]
Solomon S, Das S, Brand R, Whitcomb DC. Inherited pancreatic cancer syndromes. Cancer J 2012; 18: 485-91.
[95]
McWilliams R, Highsmith WE, Rabe KG, et al. Cystic fibrosis transmembrane regular gene carrier status is a risk factor for young onset pancreatic adenocarcinoma. Gut 2005; 54: 661-2.
[96]
American Diabetes Association AD Classification and diagnosis of diabetes. Diabetes Care 2016; 39(Suppl. 1): S13-22.
[97]
Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (Type 3c) — Are we neglecting an important disease? Eur J Intern Med 2013; 24(3): 203-6.
[98]
Couet C, Genton P, Pointel JP, et al. The prevalence of retinopathy is similar in diabetes mellitus secondary to chronic pancreatitis with or without pancreatectomy and in idiopathic diabetes mellitus. Diabetes Care 1985; 8(4): 323-8.
[99]
Duggan SN, Ewald N, Kelleher L, Griffin O, Gibney J, Conlon KC. The nutritional management of type 3c (pancreatogenic) diabetes in chronic pancreatitis. Eur J Clin Nutr 2017; 71(1): 3-8.
[100]
Linde J, Nilsson LH, Barany FR. Diabetes and hypoglycemia in chronic pancreatitis. Scand J Gastroenterol 1977; 12(3): 369-73.
[101]
Tiengo A, Segato T, Briani G, et al. The presence of retinopathy in patients with secondary diabetes following pancreatectomy or chronic pancreatitis. Diabetes Care 1983; 6(6): 570-4.
[102]
Briani G, Riva F, Midena E, et al. Prevalence of microangiopathic complications in hyperglycemia secondary to pancreatic disease. J Diabet Complications 1988; 2(1): 50-2.
[103]
Ziegler O, Candiloros H, Guerci B, Got I, Crea T, Drouin P. Lower-extremity arterial disease in diabetes mellitus due to chronic pancreatitis. Diabete Metab 1994; 20(6): 540-5.
[105]
Liao KF, Lai SW, Li CI, Chen WC. Diabetes mellitus correlates with increased risk of pancreatic cancer: A population-based cohort study in Taiwan. J Gastroenterol Hepatol 2012; 27(4): 709-13.
[106]
Munigala S, Singh A, Gelrud A, Agarwal B. Predictors for pancreatic cancer diagnosis following new-onset diabetes mellitus. Clin Transl Gastroenterol 2015; 6(10)e118
[107]
Brodovicz KG, Kou TD, Alexander CM, et al. Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk. Diabetes Obes Metab 2012; 14(12): 1123-8.
[108]
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the american diabetes association and the european association for the study of diabetes. Diabetes Care 2009; 32(1): 193-203.
[109]
Rickels MR, Bellin M, Toledo FG, et al. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: Recommendations from PancreasFest 2012. Pancreatology 2013; 13(4): 336-42.
[110]
Lund SS, Tarnow L, Astrup AS, et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A Randomized Study. PLoS One 2008; 3(10)e3363
[111]
Wang Z, Lai ST, Xie L, et al. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract 2014; 106(1): 19-26.
[112]
Li D, Yeung SJ, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137(2): 482-8.
[113]
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330(7503): 1304-5.
[114]
Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: A systematic review and meta-analysis. Am J Gastroenterol 2013; 108(4): 510-9.
[115]
Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 2011; 54(2): 339-49.
[116]
Sadeghi N, Abbruzzese JL, Yeung SCJ, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012; 18(10): 2905-12.
[117]
Banerjee A, Onyuksel H. A novel peptide nanomedicine for treatment of pancreatogenic diabetes. Nanomedicine 2013; 9(6): 722-8.
[118]
American Diabetes Association Standards of medical care in diabetes 2018. Diabetes Care 2018; 41(Suppl. 1): 1-172.
[119]
Conlon KC, Duggan SN. Pancreatogenic type 3c diabetes: underestimated, underappreciated and poorly managed. Pract Gastroenterol 2017; 15.
[121]
Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes 2010; 59(5): 1117-25.
[122]
Riccardi G, Giacco R, Parillo M, et al. Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabet Med 1999; 16(3): 228-32.
[123]
Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29(2): 254-8.
[124]
Ebert R, Creutzfeldt W. Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia 1980; 19(3): 198-204.
[125]
Klapdor S, Richter E, Klapdor R. Vitamin D status and per-oral vitamin D supplementation in patients suffering from chronic pancreatitis and pancreatic cancer disease. Anticancer Res 2012; 32(5): 1991-8.
Article Metrics
175
13
3
1